6533b829fe1ef96bd128974f
RESEARCH PRODUCT
Role of antiemetic prophylaxis for breast cancer (BC) patients treated with anti-HER2 or anti-VEGF monoclonal antibodies.
Giuseppe GalantiPaolo AmariGiuseppe BronteLivio BlasiVincenzo AdamoSilvana BavettaMaria Antonietta AspanãƒâMassimiliano AlùSceila AffrontiAntonio RussoAntonella UssetGiovanni Orlandosubject
Anti vegfCancer Researchbusiness.industrymedicine.drug_classmedicine.diseaseMonoclonal antibodyBreast cancerOncologyCancer researchMedicineAntiemeticAnti her2Cytotoxicitybusinessdescription
e20705 Background: To date the anti-emetic prophylaxis based on the combination of 5HT3-antagonists and corticosteroids is mandatory for high and moderate emetogenic cytotoxic agents. This approach...
year | journal | country | edition | language |
---|---|---|---|---|
2014-05-20 | Journal of Clinical Oncology |